APA (7th ed.) Citation

R, A., DL, B., M, S., CP, C., LA, L., SE, I., . . . PG, S. (2025). Effect of sotagliflozin on major adverse cardiovascular events: A prespecified secondary analysis of the SCORED randomised trial. The lancet. Diabetes & endocrinology, 13(4), 321. https://doi.org/10.1016/S2213-8587(24)00362-0

Chicago Style (17th ed.) Citation

R, Aggarwal, et al. "Effect of Sotagliflozin on Major Adverse Cardiovascular Events: A Prespecified Secondary Analysis of the SCORED Randomised Trial." The Lancet. Diabetes & Endocrinology 13, no. 4 (2025): 321. https://doi.org/10.1016/S2213-8587(24)00362-0.

MLA (9th ed.) Citation

R, Aggarwal, et al. "Effect of Sotagliflozin on Major Adverse Cardiovascular Events: A Prespecified Secondary Analysis of the SCORED Randomised Trial." The Lancet. Diabetes & Endocrinology, vol. 13, no. 4, 2025, p. 321, https://doi.org/10.1016/S2213-8587(24)00362-0.